Published in Br J Cancer on May 01, 1991
Breast cancer before age 40 years. Semin Oncol (2009) 2.71
The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs (2009) 1.41
The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol (2010) 1.18
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer (1995) 0.84
Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: results of a registry of female cancer patients at 2 years. J Assist Reprod Genet (2011) 0.82
Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. Br J Cancer (2004) 0.77
Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature. Menopause (2015) 0.75
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer. Cancer Res Treat (2016) 0.75
Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83
Analysis of survival by tumor response. J Clin Oncol (1983) 5.91
A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med (1984) 2.06
The role of prophylactic castration in the therapy of human mammary cancer. Eur J Cancer (1967) 1.80
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol (1987) 1.59
The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol (1990) 1.56
Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet (1986) 1.30
Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer (1977) 1.29
Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet (1981) 1.15
Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res (1980) 1.13
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet (1988) 0.97
Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol (1987) 0.89
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res (2000) 3.95
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Mental health research priorities in low- and middle-income countries of Africa, Asia, Latin America and the Caribbean. Br J Psychiatry (2009) 3.11
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab (2000) 2.43
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res (2001) 2.29
Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology (1995) 2.12
Informed versus randomised consent to clinical trials. Lancet (1995) 2.07
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer (1999) 1.90
Gastrointestinal symptoms in patients with asthma. Arch Dis Child (2000) 1.82
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res (2000) 1.82
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol (1996) 1.74
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res (1999) 1.66
Diagnosis of cysticercosis in endemic regions. The Cysticercosis Working Group in Peru. Lancet (1991) 1.63
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut (2001) 1.61
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol (2005) 1.54
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Immunodiagnosis of human cysticercosis (Taenia solium): a field comparison of an antibody-enzyme-linked immunosorbent assay (ELISA), an antigen-ELISA, and an enzyme-linked immunoelectrotransfer blot (EITB) assay in Peru. The Cysticercosis Working Group in Peru (CWG). Am J Trop Med Hyg (1992) 1.53
Constitutive RNA synthesis for the yeast activator ADR1 and identification of the ADR1-5c mutation: implications in posttranslational control of ADR1. Mol Cell Biol (1986) 1.49
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast (2010) 1.47
Whole-genome organization and functional properties of miniature DNA insertion sequences conserved in pathogenic Neisseriae. Gene (2001) 1.47
Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol (2008) 1.31
Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol (1995) 1.30
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol (2009) 1.30
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer (2004) 1.26
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? Eur J Cancer (1996) 1.26
The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer (1995) 1.25
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer (2004) 1.20
Lung cancer in the elderly. Eur J Cancer (1997) 1.19
Intestinal side-effects of docetaxel/vinorelbine combination. Lancet (2000) 1.19
Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev (2010) 1.19
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
A randomized clinical trial comparing 22G and 25G needles in endoscopic ultrasound-guided fine-needle aspiration of solid lesions. Endoscopy (2011) 1.15
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (1996) 1.13
Long-term sonographic follow-up of rheumatoid and psoriatic proliferative knee joint synovitis. Br J Rheumatol (1996) 1.13
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol (2009) 1.10
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer (2006) 1.09
Analysis of ferritins in lymphoblastoid cell lines and in the lens of subjects with hereditary hyperferritinemia-cataract syndrome. Blood (1998) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res (2000) 1.02
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol (2011) 1.02
Child survivors of suicide: psychosocial characteristics. J Am Acad Child Adolesc Psychiatry (1997) 1.00
Posture and movement in healthy preterm infants in supine position in and outside the nest. Arch Dis Child Fetal Neonatal Ed (2007) 0.99
Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology (1995) 0.99
Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer (1996) 0.99
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet (1988) 0.97
Early phenotypic activation of circulating helper memory T cells in scleroderma: correlation with disease activity. Ann Rheum Dis (1993) 0.97
Quality of life in lung cancer patients. Ann Oncol (2001) 0.95
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol (2009) 0.95
Predicting mood disorders in breast cancer patients. Eur J Cancer (2001) 0.94
Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol (2011) 0.94
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat (2012) 0.94
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol (2013) 0.94
The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol (1999) 0.93
Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer (1997) 0.93
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Ann Oncol (2009) 0.92
[Carcinoid of Meckel's diverticulum]. Minerva Chir (1995) 0.92
The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. Ann Oncol (1998) 0.91
Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. Breast Cancer Res Treat (1990) 0.91
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Ann Oncol (2006) 0.91
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab (2000) 0.91
Challenges to reduce the '10/90 gap': mental health research in Latin American and Caribbean countries. Acta Psychiatr Scand (2008) 0.91
Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis (2005) 0.91
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Res Treat (2012) 0.90
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol (1996) 0.90
Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol (1999) 0.89
Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis (2010) 0.89
[Color Doppler-echo in rheumatoid arthritis with extra-articular location. Preliminary experience]. Radiol Med (1999) 0.89
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer (2000) 0.89
Evolution and function of the neisserial dam-replacing gene. FEBS Lett (2001) 0.89
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol (2011) 0.89
Prevalence of Toxocara cati and other parasites in cats' faeces collected from the open spaces of public institutions: Buenos Aires, Argentina. Vet Parasitol (2006) 0.89
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol (2005) 0.89